БЛОГ

Aug 27, 2020

Cardiology trial shows potential benefit of genetic testing when selecting blood thinners

Posted by in categories: biotech/medical, genetics

An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 percent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

For patients undergoing (PCI)—a non-surgical procedure where physicians inflate a balloon and place a metal stent in narrowed arteries to improve to the heart —the choice of antiplatelet therapy can be critical to post-treatment success, and to minimize the chance of heart attack or stroke.

The TAILOR-PCI trial, co-led by principal investigators Dr. Michael Farkouh, cardiologist and Multinational Clinical Trials Chair at the Peter Munk Cardiac Centre and Dr. Naveen Pereira, Professor of Medicine and cardiologist at Mayo Clinic, studied the effectiveness of genetic-guided therapy in patients that have had PCIs when compared to conventional therapy.

Comments are closed.